Side-by-side · Research reference

PinealonvsPTD-DBM

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED12/36 cited

BAnimal-StrongHUMAN-REVIEWED10/40 cited

Pinealon

Pineal-derived · Neuroprotective

5–10 mgPer cycle doseKhavinson 2014

HumanMechanisticKhavinson 2014

HoursHalf-life (est)

SQ or IM · Daily for 10 days · 1-2×/year

PTD-DBM

Wnt Pathway Activator · Fusion Peptide

Topical / SQAdministrationLee 2023 Ryu 2023

Animal-onlyEvidence level

Wnt/β-cateninPrimary pathway

Topical / SQ · Study-dependent

01Mechanism of Action

Parameter

Pinealon

PTD-DBM

Primary target

Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014

CXXC5–Dishevelled protein-protein interaction

Pathway

Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014

Inhibit CXXC5 binding to Dishevelled → Release Wnt/β-catenin pathway inhibitionLee 2015 Ryu 2023

Downstream effect

Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014

Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation

Feedback intact?

—

Not applicable — pathway derepression rather than receptor agonism

Origin

Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014

Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5

Antibody development

—

02Dosage Protocols

Parameter

Pinealon

PTD-DBM

Standard dose

5–10 mg / day for 10 daysKhavinson 2014

—

Frequency

Once daily during cycle

—

Lower / starter dose

2.5 mg / day

—

Evidence basis

Russian clinical trials + in vitroKhavinson 2014

Animal models only (mice)

Duration

10-day cycles, 1–2× per year

—

Reconstitution

Bacteriostatic water

—

Timing

No specific time

—

Half-life

Hours

—

Wound healing protocol

—

Hydrogel patch delivery (concentration not disclosed)

Pyrogallol-HA patch, murine model.

Hair regeneration protocol

—

Topical application (exact dose not disclosed)

Wound-induced hair neogenesis model, mice.

Co-administration

—

Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023

Combined treatment maximized scar reduction.

Human translation

—

No published human studies

04Side Effects & Safety

Parameter

Pinealon

PTD-DBM

Injection site reaction

Mild irritation

—

Long-term safety

Limited Western data

Unknown — no chronic dosing or human data

Pregnancy / OB

Avoid

—

Reported adverse events

—

None reported in animal studies

Wnt pathway activation risks

—

Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis

Delivery vehicle effects

—

HA-PG hydrogel well-tolerated in mice; human translation pending

Absolute Contraindications

Pinealon

·Pregnancy / breastfeeding

PTD-DBM

·Active malignancy (Wnt pathway involvement in tumorigenesis)
·Pregnancy / lactation (no safety data)

Relative Contraindications

Pinealon

·Active malignancy (theoretical via gene expression modulation)

PTD-DBM

·History of Wnt-driven tumors
·Skin lesions with uncertain malignant potential

05Administration Protocol

Parameter

Pinealon

PTD-DBM

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial.

Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023

2. Injection site

SQ — abdomen preferred.

Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023

3. Timing

Daily during cycle, any time.

PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Not disclosed in available literature. Peptide stability and storage conditions not published.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

Pinealon

+ Epitalon

Moderate

View Epitalon →

Pinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.

Pinealon: 5–10 mg SQ · daily × 10 days
Epitalon: 5–10 mg SQ · daily × 10 days (overlap or alternate)
Primary benefit: Neuroprotection + telomere preservation

Khavinson 2014 Khavinson 2003

PTD-DBM

— no documented stacks